Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Impact of Induction Immunosuppression on the Recurrence of Primary IgA Nephropathy.

Lee KW, Kim KS, Lee JS, Yoo H, Kim K, Park JB, Kwon GY, Kim SJ.

Transplant Proc. 2019 Jun;51(5):1491-1495. doi: 10.1016/j.transproceed.2019.01.115. Epub 2019 Apr 19.

PMID:
31010698
2.

The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.

Von Visger JR, Gunay Y, Andreoni KA, Bhatt UY, Nori US, Pesavento TE, Elkhammas EA, Winters HA, Nadasdy T, Singh N.

Clin Transplant. 2014 Aug;28(8):845-54. doi: 10.1111/ctr.12389. Epub 2014 Jun 24.

PMID:
24869763
3.

Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy.

Berthoux F, El Deeb S, Mariat C, Diconne E, Laurent B, Thibaudin L.

Transplantation. 2008 May 27;85(10):1505-7. doi: 10.1097/TP.0b013e3181705ad4.

PMID:
18497694
4.

IgA NEPHROPATHY IN PATIENTS RECEIVING A RENAL TRANSPLANT.

Lemes-Canuto AP, de Sandes-Freitas TV, Medina-Pestana JO, Mastroianni-Kirsztajn G.

J Ren Care. 2015 Dec;41(4):222-30. doi: 10.1111/jorc.12122. Epub 2015 Mar 26.

PMID:
25819382
5.

Steroids and recurrent IgA nephropathy after kidney transplantation.

Clayton P, McDonald S, Chadban S.

Am J Transplant. 2011 Aug;11(8):1645-9. doi: 10.1111/j.1600-6143.2011.03667.x.

6.

Early post-transplant serum IgA level is associated with IgA nephropathy recurrence after kidney transplantation.

Garnier AS, Duveau A, Demiselle J, Croué A, Subra JF, Sayegh J, Augusto JF.

PLoS One. 2018 Apr 25;13(4):e0196101. doi: 10.1371/journal.pone.0196101. eCollection 2018.

7.

Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.

Lü TM, Yang SL, Wu WZ, Tan JM.

Chin Med J (Engl). 2011 Mar;124(5):664-8.

PMID:
21518554
8.

Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.

Kesiraju S, Paritala P, Rao Ch UM, Athmakuri SM, Reddy VS, Sahariah S.

Saudi J Kidney Dis Transpl. 2014 Jan;25(1):9-15.

9.

Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.

Leeaphorn N, Garg N, Khankin EV, Cardarelli F, Pavlakis M.

Transpl Int. 2018 Feb;31(2):175-186. doi: 10.1111/tri.13075. Epub 2017 Oct 12.

10.

Single-center long-term results of renal transplantation for IgA nephropathy.

Bumgardner GL, Amend WC, Ascher NL, Vincenti FG.

Transplantation. 1998 Apr 27;65(8):1053-60.

PMID:
9583865
11.

A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.

Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD.

Chin Med J (Engl). 2012 Mar;125(6):1135-40.

PMID:
22613543
12.

Long-term Clinical Outcomes of First and Second Kidney Transplantation in Patients With Biopsy-Proven IgA Nephropathy.

Kim Y, Yeo SM, Kang SS, Park WY, Jin K, Park SB, Park UJ, Kim HT, Han S.

Transplant Proc. 2017 Jun;49(5):992-996. doi: 10.1016/j.transproceed.2017.03.063.

PMID:
28583574
13.

Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.

Whitson BA, Kilic A, Lehman A, Wehr A, Hasan A, Haas G, Hayes D Jr, Sai-Sudhakar CB, Higgins RS.

Clin Transplant. 2015 Jan;29(1):9-17. doi: 10.1111/ctr.12469. Epub 2014 Dec 12.

PMID:
25284138
14.

Favorable outcome of renal transplantation in patients with IgA nephropathy.

Andresdottir MB, Hoitsma AJ, Assmann KJ, Wetzels JF.

Clin Nephrol. 2001 Oct;56(4):279-88.

PMID:
11680657
15.

Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin.

Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F.

Nephrol Dial Transplant. 1998 Mar;13(3):711-5.

PMID:
9550651
16.

Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.

Horton PJ, Tchervenkov J, Barkun JS, Rochon C, Chaudhury PK, Znajda TL, Martinie JB, Metrakos P.

J Gastrointest Surg. 2005 Sep-Oct;9(7):896-902.

PMID:
16137581
17.

Disparate rates of acute rejection and donor-specific antibodies among high-immunologic risk renal transplant subgroups receiving antithymocyte globulin induction.

Patel SJ, Suki WN, Loucks-DeVos J, Graviss EA, Nguyen DT, Knight RJ, Kuten SA, Moore LW, Teeter LD, Gaber LW, Gaber AO.

Transpl Int. 2016 Aug;29(8):897-908. doi: 10.1111/tri.12791. Epub 2016 Jul 7.

18.

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents.

Avasare RS, Rosenstiel PE, Zaky ZS, Tsapepas DS, Appel GB, Markowitz GS, Bomback AS, Canetta PA.

Am J Nephrol. 2017;45(2):99-106. doi: 10.1159/000453081. Epub 2017 Jan 6.

19.

Higher Incidence of Renal Allograft Glomerulonephritis in Living-Related Donor Kidney Transplantation.

Deng R, Dai Y, Zhang H, Liu L, Li J, Xiong Y, Deng S, Fu Q, Wang C.

Transplant Proc. 2018 Oct;50(8):2421-2425. doi: 10.1016/j.transproceed.2018.03.050. Epub 2018 Mar 15.

PMID:
30316370
20.

Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.

Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.

Transpl Immunol. 2008 Jan;18(3):281-5. Epub 2007 Aug 28.

PMID:
18047938

Supplemental Content

Support Center